PhotonPharma Secures $2.5 Million in Seed Funding for Groundbreaking Immuno-Oncology Technology Development

PhotonPharma is thrilled to announce that it has successfully raised $2.5 million in funding to further advance its groundbreaking immuno-oncology technology. As a pioneer in the field, PhotonPharma has developed a unique approach that empowers a patient’s own immune system to identify and eradicate cancer cells. Our patented process is revolutionary in that it meticulously inactivates the DNA/RNA of a patient’s tumor cells while preserving their integrity, ensuring that the crucial tumor-specific antigen targets—known as neoantigens—remain intact. This innovative treatment enables the extraction, inactivation, and administration of tumor cells to be conducted on the same day, rendering it not only simple and fast but also cost-effective. The successful results observed in our previous dog and mouse trials have set a strong foundation for the efficacy and safety of our technology. With this new funding, PhotonPharma aims to accelerate its clinical trial processes and expand its research efforts to bring this life-saving solution to patients battling cancer. Our commitment to harnessing the power of the immune system marks a significant step forward in cancer treatment, and we are excited to be at the forefront of this transformative journey. We are profoundly grateful to our investors for their belief in our vision and look forward to sharing further developments as we move ahead in our mission to empower patients in their fight against cancer.